upgrad three week
fisher paykel healthcar morn upgrad npat guidanc
previous midpoint second upgrad
nearli mani week coronaviru becom widespread outsid
china fph seen materi increas hospit hardwar sale fx tailwind
lower nzd usd better expect sale legaci mask homecar
segment also drove upgrad
upgrad weight hospit divis surg demand
humidifiers/hospit hardwar product china continu expand fph
major market eu/u extend reach europ us singl use
mask market thu attract long term
fx homecar improv add npat
whilst fph hedg intern revenu spike demand china/eu led
fx tailwind unhedg revenu upgrad addit homecar sale
upgrad continu improv better expect sale legaci
mask compliment steadi uptak new vitera mask
reiter under-perform valuat
attract growth potenti fph hospit segment howev
reiter under-perform given rich valuat forward estimate price-to-earnings expand
std dev histor averag prefer trade
lower multipl similar ep growth amend forecast reflect today
guidanc npat increas previous po lift per
share fph releas earn
full definit iqmethod sm measur see page
employ non-u affili bofa registered/qualifi research analyst
finra rule
refer import disclosur inform certain bofa secur entiti take
respons inform herein particular jurisdict
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
outsid equiti interest npat
chang work capit
 flow item int tax
 flow oper
oper
acquisit dispos invest
 flow invest
invest
 flow financ
financ
return capit employ
return equiti
iqmethod sm qualiti earn
full definit iqmethod sm measur see page
fisher paykel healthcar fph market
leader in-pati hospit humidif
top player global obstruct sleep apnea
market high margin busi attract
long term growth prospect support
attract in-hospit humidif
market howev believ potenti
alreadi reflect rich valuat stock
price appreci last twelv
month ep revis near
term result unlik hold upsid
surpris compani upgrad
earn twice year basi rate
price book valu
dcf-base price object per share translat us dollar
valuat aud/usd exchang rate reflect current spot rate
dcf valuat use risk-fre rate histor beta
market risk premium provid wacc termin growth rate
downsid risk price object delay setback plasma collect
centr open unfavour result phase trial competitor
launch new challeng drug loss momentum seqiru chang
reimburs polici breakthrough gene therapi
price object base sum-of-the-part ev/ebitda methodolog
hospit premium australian peer reflect superior revenu
growth ep growth roce homecar discount sleep apnea
market leader po equat forward price-to-earnings
upsid risk growth hospit new applic revenu expans
healthcar budget reimburs earlier launch faster uptak new osa
mask favour exchang rate
downsid risk chang healthcar budgets/reimburs competitor launch
price object per share base dcf
valuat dcf use wacc termin growth rate beta
downsid risk po loss momentum saa busi market
educ effort achiev expect revenu growth reimburs
chang health ministri phi poor recept new product launch
technolog advanc competitor product fx chang
lyann harrison herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
